Organon & Co.

For the period ended Sep 30, 2026. Filed Oct 30, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Oct 30, 2026

OGN$13.89+0.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Product and Geographic Information

Product and Geographic Information

Revenues of the Company’s products were as follows:

Three Months Ended September 30, · Nine Months Ended September 30,
	2026			2025			2026			2025
($ in millions)	U.S.	Int’l	Total	U.S.	Int’l	Total	U.S.	Int’l	Total	U.S.	Int’l	Total
Women’s Health
Nexplanon/Implanon NXT	$127	$73	$200	$146	$77	$223	$383	$248	$631	$486	$225	$711
Follistim AQ	32	35	67	24	40	64	70	117	188	89	117	206
NuvaRing	6	19	25	9	17	26	20	56	76	21	54	75
Ganirelix Acetate Injection	4	21	24	3	19	22	7	69	76	10	67	77
Marvelon/Mercilon	—	28	28	—	31	31	—	85	85	—	103	103
Jada (3)	—	—	—	20	—	20	5	—	5	53	1	54
Other Women’s Health (1)	14	29	45	17	26	43	48	88	135	47	80	128
General Medicines
Biosimilars
Renflexis	46	21	67	51	19	70	133	57	190	141	49	190
Hadlima	62	24	86	47	16	63	168	64	231	116	44	159
Ontruzant	4	3	7	4	28	31	13	5	18	12	68	80
Brenzys	—	22	22	—	23	23	—	56	56	—	59	59
Bildyos/Bilprevda	17	7	24	3	—	3	37	23	60	3	—	3
Other Biosimilars (1)	10	2	13	3	3	6	25	7	32	6	13	19
Established Brands
Cardiovascular
Atozet	—	85	85	—	95	95	—	250	250	—	257	257
Zetia	1	100	101	1	91	93	4	280	284	4	248	252
Cozaar/Hyzaar	2	49	51	2	53	55	6	152	158	6	160	166
Vytorin	1	24	25	1	25	25	4	64	68	3	72	75
Rosuzet	—	5	5	—	6	6	—	16	16	—	16	16
Other Cardiovascular (1)	1	34	35	1	33	33	1	85	87	1	97	98
Respiratory
Singulair	2	43	45	2	51	53	6	127	132	6	187	193
Nasonex	—	65	65	—	60	60	—	188	188	—	197	197
Dulera	25	10	35	24	10	34	78	33	111	89	28	118
Clarinex	—	23	23	1	25	25	2	83	85	1	92	93
Other Respiratory (1)	11	3	14	9	2	12	38	5	44	32	9	40
Non-Opioid Pain, Bone and Dermatology
Arcoxia	—	69	69	—	71	71	—	197	197	—	195	195
Fosamax	1	28	28	—	40	40	2	80	82	2	106	107
Diprospan	—	42	42	—	41	41	—	121	121	—	112	112
Vtama	38	4	42	31	3	34	95	7	102	80	9	89
Other Non-Opioid Pain, Bone and Dermatology (1)	3	71	75	4	75	80	10	212	222	11	217	229
Other
Propecia	1	40	41	2	31	33	4	102	106	4	86	90
Emgality	—	59	59	—	51	51	—	166	166	—	125	125
Proscar	—	22	22	—	27	27	1	68	69	1	73	73
Other (1)	3	91	93	—	86	88	7	270	277	6	245	253
Other (2)	—	12	11	1	21	21	—	44	44	2	66	67
Revenues	$411	$1,163	$1,574	$406	$1,196	$1,602	$1,167	$3,425	$4,592	$1,232	$3,477	$4,709

Totals may not foot due to rounding. Trademarks appearing above in italics are trademarks of, or are used under license by, the Organon group of companies unless otherwise indicated.

(1) Includes sales of products not listed separately.

(2) Includes manufacturing sales to third parties.

(3)Jada is a trademark registered in the US in the name of Alydia Health, Inc.

-12-

Revenues by geographic area where derived are as follows:

	Three Months EndedSeptember 30,		Nine Months EndedSeptember 30,
($ in millions)	2026	2025	2026	2025
Europe and Canada	$417	$417	$1,262	$1,212
United States	411	406	1,167	1,232
Asia Pacific and Japan	234	251	691	752
China	226	219	629	627
Latin America, Middle East, Russia, and Africa	269	286	785	810
Other (1)	17	23	58	76
Revenues	$1,574	$1,602	$4,592	$4,709

(1) Includes manufacturing sales to third parties.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.